bioRxivCancer BiologyPreprint
HES1 oscillations are required for cell cycle re-entry in oestrogen receptor positive breast cancer cells
Oliver CottrelliD, Andrew RowntreeiD, Kunal ChopraiD, Eleanor Mackellar, Benjamin NobleiD, Hannah Dixon, Ciara Healy, Robert B. ClarkeiD, Nancy PapalopuluiD
Abstract
Long-term recurrence in breast cancer is driven by reactivation of dormant disseminated tumour cells (DTCs) and remains a major clinical challenge, particularly in oestrogen receptor positive (ER) tumours. This process is underpinned by regulation of the cell cycle machinery that controls quiescence maintenance and exit. HES1, a Notch pathway transcription factor, regulates key cell cycle genes and has been shown to demonstrate protein expression oscillations. Here, we sought to establish whether HES1 oscillations may regulate ER+ cancer cell quiescence and reactivation. To investigate this, we developed a fundamental in vitro model of cell cycle arrest and re-entry based on reversible CDK4/6 inhibition (CDK4/6i) with palbociclib, compatible with quantitative single-cell live-imaging of a knock-in endogenous HES1 reporter. Consistent with earlier findings, HES1 exhibited [~]24-hour protein oscillations in cycling cells demonstrating a reproducible dip in protein expression prior to S-Phase. During CDK4/6i-mediated arrest, the [~]24h HES1 oscillation was lost, HES1 levels were maintained at a moderately higher level and HES1 exhibited smaller dips. Similar changes were observed in unperturbed, spontaneously quiescent cells. Following release from CDK4/6i and cell cycle re- entry, these alterations were reversed and the characteristic G1/S HES1 dip was observed. Preventing this dip at the point of release, by inducibly sustaining HES1 with a Tet-On system, upregulated the cell cycle inhibitor p21, impeded cell cycle re-entry and induced cell death. These findings suggest that manipulating HES1 dynamics could represent a promising therapeutic approach to prevent reactivation of dormant tumour cells. Significance StatementBreast cancer can recur years after initial treatment due to reactivation of dormant tumour cells. Understanding how these cells exit dormancy is crucial for preventing relapse. We investigated HES1, a transcription factor with rhythmic protein oscillations, and its role in regulating quiescence in oestrogen receptor-positive (ER) breast cancer cells. Using live-cell imaging and a reversible cell cycle arrest model, we show that HES1 dynamics change during dormancy and reactivation, and that disrupting these oscillations prevents cell cycle re-entry and induces cell death. These findings reveal HES1 protein dynamics as a potential therapeutic vulnerability and highlight a novel strategy to target dormant cancer cells to prevent their reactivation.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- approach: experimental assay
- Citations
- 3
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Differential phase register of Hes1 oscillations with mitoses underlies cell-cycle heterogeneity in ER+ breast cancer cells.
N. Sabherwal, A. Rowntree, … N. Papalopulu·bioRxiv·Jan 4, 2021
- HES1 protein oscillations are necessary for neural stem cells to exit from quiescence
E. Marinopoulou, N. Sabherwal, … N. Papalopulu·iSciencePeer-reviewed·Oct 1, 2021
- WEE1 inhibition delays resistance to CDK4/6 inhibitor and antiestrogen treatment in estrogen receptor-positive breast cancer
Wei He, Diane M. Demas, … William T. Baumann·npj Systems Biology and ApplicationsPeer-reviewed·Nov 17, 2025
- ErbB2/HER2 governs CDK4 inhibitor sensitivity and timing and irreversibility of G1/S transition by altering c-Myc and cyclin D function
Ayaka Ichikawa Nagasato, Ken Murakami, … Mariko Okada·Journal of Biological ChemistryPeer-reviewed·Oct 28, 2025
- Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells
T. M. Zikry, S. C. Wolff, … J. E. Purvis·bioRxiv·May 22, 2023
- Breast cancer dormancy is associated with a 4NG1 state and not senescence
C. Prunier, A. Alay, … L. Ritsma·bioRxiv·Nov 20, 2020